Exclusion Criteria:~1. Non-AD-induced memory and cognitive impairment, such as a diagnosis of other types of
dementia, including, but not limited to, Mixed Disease Dementia, Vascular Dementia, Parkinson's Disease
Dementia, Lewy Body Dementia, Huntington's Chorea-related Dementia, Normal Pressure Hydrocephalus, Brain
Tumour, Progressive Supranuclear Palsy, Frontotemporal Lobar Dementia, etc.; Endocrine system pathology (e.g.,
Thyroid Disease, Parathyroid Disease) as well as Folic Acid, Vitamin B12 deficiency or any other causes of
dementia; the presence of impaired consciousness, etc;~2. A history of seizures; psychosis, including but not
limited to schizophrenia, schizoaffective disorder, bipolar disorder, or delirium; and~3. Hamilton Depression
Scale (HAMD) score >17;~4. Significant focal lesions on MRI with one of the following: a. >2 infarct foci >2cm
in diameter; b. Infarct foci in key areas such as thalamus, hippocampus, internal olfactory cortex, parafrontal
olfactory cortex, angular gyrus, cortex, and other subcortical grey matter nuclei; and c. Cerebral white matter
damage with a Fazekas Scale score ≥3;~5. Patients who have taken other herbal preparations within the past 1
month;~6. Astragalus allergy or contraindication;~7. Presence of abnormal laboratory parameters: impaired renal
function (blood Cr > 1.5xULN) or creatinine clearance (C cr) < 50mL/min or abnormal liver function (ALT or AST
> 2xULN);~8. Patients who refused or had contraindications to MRI or EEG (pacemakers, coronary and peripheral
arterial stents, metallic implants, claustrophobia, or severe visual or hearing impairments); refused to have
blood drawn;~9. Hachinski Ischaemia Scale score ≥ 4;~10. Pregnant or breastfeeding patients; and~11. Other
unmanageable clinical problems (e.g. neoplasms, HIV infection, syphilis spirochete infection, hepatitis C virus
infection, active hepatitis B or other severe chronic infectious diseases, severe neurological, cardiovascular,
respiratory and other systemic diseases);~12. Patients who have participated in other clinical studies within
the past 3 months;~13. Those who, in the opinion of the investigator, need to be excluded
